date,title,source
Oct-23-18,Provention Bio Announces Completion of Enrollment of Phase 1b Clinical Trial of PRV-300 in Moderate-to-Severe Ulcerative Colitis,PR Newswire
Nov-05-18,Amgen And Provention Bio Announce Co-Development Collaboration In Celiac Disease,PR Newswire
Nov-08-18,Provention Bio Reports Third Quarter 2018 Financial Results and Provides Business Update,PR Newswire
Nov-28-18,Provention Bio Joins the C-Path Type 1 Diabetes (T1D) Consortium,PR Newswire
Dec-25-18,"Are Insiders Buying Provention Bio, Inc. (NASDAQ:PRVB) Stock?",Simply Wall St.
Jan-03-19,"Provention Bio Announces Publication in ""Expert Review of Vaccines"" Describing the Scientific Rationale for Developing a Vaccine for Type 1 Diabetes by Targeting Coxsackievirus B",PR Newswire
Jan-28-19,Provention Bio Receives Notice of Allowance from United States Patent and Trademark Office for Patent on Multi-Strain Coxsackievirus B Vaccine for Preventing or Treating Type 1 Diabetes (T1D),PR Newswire
Feb-13-19,Provention Bio To Present at 8th Annual Leerink Partners Global Healthcare Conference,PR Newswire
